Zimmer Biomet Stock Price, News & Analysis

Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for the third quarter of 2021. This dividend will be payable on October 29, 2021 to shareholders on record as of September 30, 2021. The company, a leader in medical technology, is known for its innovative solutions aimed at improving health and mobility. Zimmer Biomet operates globally, contributing to advancements in patient care through integrated digital and robotic technologies.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced four presentations at the AAOS 2021 Annual Meeting showcasing the clinical value of mymobility with Apple Watch. This remote care management platform aids healthcare professionals in supporting patients pre- and post-orthopedic procedures. Initial findings from the ongoing mymobility Clinical Study suggest that patients using the platform experience similar outcomes to traditional care, potentially lowering postoperative costs. The conference is taking place from August 31 to September 3, 2021 in San Diego.

Zimmer Biomet Holdings (ZBH) announced that Chairman Bryan Hanson and CFO Suky Upadhyay will present at Baird's 2021 Virtual Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website. The company specializes in medical technology, focusing on enhancing patient mobility through innovative products and digital technologies. Zimmer Biomet operates in over 25 countries, with sales in more than 100 countries, and boasts over 90 years of industry experience.

Zimmer Biomet Holdings (NYSE: ZBH) has received FDA 510(k) clearance for its ROSA® Hip System, enhancing its robotic surgical portfolio. This system aids in robotically-assisted direct anterior total hip replacement, offering surgeons real-time data and control over surgical procedures. ROSA Hip integrates with ZBEdge and mymobility® technologies to improve patient outcomes and streamline surgical workflows. Designed for compatibility with various implant systems, it aims to enhance procedural efficiency and mitigate intra-operative variability.

Zimmer Biomet Holdings announced six key data presentations at the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting scheduled for August 31 to September 3 in San Diego. Highlights include a podium presentation of the investigational Persona IQ smart knee implant and three posters detailing the clinical utility of the mymobility remote care management platform. The company is set to showcase its latest technologies, including the ROSA Hip, which is currently under FDA review, as part of its ZBEdge Connected Intelligence suite.

Zimmer Biomet Holdings reported second-quarter 2021 net sales of $2.027 billion, a remarkable 65.3% increase from the previous year. Net earnings reached $141.9 million ($0.67 per share) with adjusted diluted EPS at $1.90. Compared to pre-pandemic Q2 2019, sales are up 1.9%. The company anticipates continued growth despite ongoing COVID-19 pressures. Zimmer Biomet has also updated its full-year 2021 guidance, projecting revenue growth of 14.5% - 16.5% and adjusted diluted EPS of $7.65 - $7.95.

ZBH will host its second quarter earnings conference call on August 3, 2021, at 8:30 a.m. ET. The financial results will be released earlier that day at 6:30 a.m. ET. Investors can access the live audio webcast on Zimmer Biomet's Investor Relations website, which will also be archived for later replay. U.S. participants can join the call by dialing (888) 312-9837 and entering the conference ID 7278985. This conference call follows Zimmer Biomet's ongoing commitment to transparency and communication with its investors.

Zimmer Biomet Holdings (ZBH) has announced a quarterly cash dividend of $0.24 per share for Q2 2021. This dividend is payable on or about July 30, 2021 to stockholders who are on record as of the close of business on June 28, 2021. The company, a leader in musculoskeletal healthcare, continues to demonstrate its commitment to returning value to its shareholders. Founded in 1927, Zimmer Biomet operates in over 25 countries, selling products in more than 100 countries.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) recently appointed Wilfred van Zuilen as President for the EMEA region and Nitin Goyal, M.D. as Chief Science, Technology and Innovation Officer. These changes aim to strengthen the company's leadership as it transitions through a pivotal business phase. Van Zuilen brings extensive experience from Medtronic, while Dr. Goyal leverages his medical background and digital innovation expertise to enhance Zimmer Biomet's product development and clinical affairs.